NCT01911065

T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020

T Cell Responses to Varicella Zoster Virus After Vaccination and Viral Escape

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Accepted

Summary

In this study the investigators are trying to identify immune signatures that are associated with effective or poor vaccine responses to naturally-acquired herpes zoster virus and the zoster (shingles) vaccine, Zostavax.

Detailed description

This study will examine the frequency, phenotype and repertoire of VZV-specific T cells. The frequency and T-Cell Receptor (TCR) diversity of VZV-specific T cells on days 7 and 14 after vaccination will be examined. The titer of anti-VZV antibodies and T cell frequencies will be examined on day 28 post vaccination.

Conditions

• Herpes Zoster

Interventions

Type	Name	Description
BIOLOGICAL	Zostavax™	In the Vaccination arm, healthy individuals will be vaccinated with the licensed zoster vaccine, Zostavax.

Timeline

• Start date: 2010-09-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2013-07-30
• Last updated: 2023-12-18
• Results posted: 2017-03-03

Locations

1 site across 1 country: United States